On Monday, Intrexon Corp (NYSE:XON)’s shares declined -3.00% to $42.39.
Intrexon Corp (XON) declared it has accomplished the acquisition of Okanagan Specialty Fruits (OSF), the pioneering agricultural company behind the Arctic® apple, the world’s first non-browning apple without the use of any flavor-altering chemical or antioxidant additives. OSF’s vision and ground-breaking effort in responsibly harnessing the power of technology to produce wholesome, nutritious food that is more appetizing and convenient to consumers is aligned with Intrexon’s strategy in the Food sector.
The combination of the talented OSF team under the continued leadership of Neal Carter, OSF Founder and President, and Intrexon’s technology platform opens the door to novel, designer foods that support the evolving healthy diet choices of consumer.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
HomeAway, Inc. (NASDAQ:AWAY)’s shares dropped -2.94% to $31.66.
HomeAway, Inc. (AWAY) declared it will report its financial results for the first quarter ended March 31, 2015 on Thursday, April 23, 2015 after the close of market. HomeAway(R) will host a conference call to review and talk about the first quarter results at 4:30 p.m. Eastern Time / 3:30 p.m. Central Time. In addition, a live webcast of the call will be accessible through the Investor Relations section of HomeAway’s website and will be archived online for 60 days upon completion of the conference call.
HomeAway, Inc., together with its auxiliaries, operates an online vacation rental property marketplace that enables property owners and managers to market properties for rental to vacation travelers.
At the end of Monday’s trade, Merrimack Pharmaceuticals Inc (NASDAQ:MACK)‘s shares dipped -2.87% to $12.71.
Merrimack Pharmaceuticals Inc (MACK) declared updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer. The results were presented recently by Patricia LoRusso, D.O., in a clinical trials plenary oral session at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. Data described the safety and promising clinical activity of MM-302 in patients with advanced HER2-positive metastatic breast cancer.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States.
Genworth Financial Inc (NYSE:GNW), ended its Monday’s trading session with -2.87% loss, and closed at $7.79.
Genworth Financial Inc (GNW) declared it will issue its earnings release and financial supplement containing the first quarter results after the market closes on April 28 , 2015. A conference call will be held the following day, April 29, at 10:00 AM (ET) to talk about the results for the quarter.
Investor materials will be accessible on the Company’s website, http://investor.genworthmicanada.ca, in advance of the call.
Genworth Financial, Inc. provides insurance, retirement, and homeownership solutions in the United States and internationally. It operates through U.S. Life Insurance, International Mortgage Insurance, U.S. Mortgage Insurance, International Protection, and Runoff segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
